E1. Evidence of malignancy ≤ 3 years prior to screening, unless deemed completely cured o E1.1 Carcinoma-in-situ allowed o E1.2 Non-melanoma skin cancer allowed o E1.3 Thymoma allowed (if no active treatment is required) E2. Known muscle disease prior to COVID-19. E3. Other factor(s) or medical condition(s) that may explain residual symptoms (affective psychiatric conditions, functional, psychosomatic disorders, endocrine disorders, etc.) E4. Pregnancy or breast-feeding E5. Treatment with beta-agonists E6. Uncontrolled diabetes E7. Ischemic Heart Disease, Cardiac Arrhythmia or Heart Failure (including hypertrophic cardiomyopathy) E8. Uncontrolled Hypertension (≥ 160/110) E9. Known hypersensitivity to any of the study drug components E10. Treatment with tricyclic antidepressants, monoaminoxidase inhibitors, digoxin, or methylxanthines.

E1. Evidence of malignancy ≤ 3 years prior to screening, unless deemed completely cured o E1.1 Carcinoma-in-situ allowed o E1.2 Non-melanoma skin cancer allowed o E1.3 Thymoma allowed (if no active treatment is required) E2. Known muscle disease prior to COVID-19. E3. Other factor(s) or medical condition(s) that may explain residual symptoms (affective psychiatric conditions, functional, psychosomatic disorders, endocrine disorders, etc.) E4. Pregnancy or breast-feeding E5. Treatment with beta-agonists E6. Uncontrolled diabetes E7. Ischemic Heart Disease, Cardiac Arrhythmia or Heart Failure (including hypertrophic cardiomyopathy) E8. Uncontrolled Hypertension (≥ 160/110) E9. Known hypersensitivity to any of the study drug components E10. Treatment with tricyclic antidepressants, monoaminoxidase inhibitors, digoxin, or methylxanthines.